Providing Process Development, Flexible Manufacturing, and Analytical Services to the Global Biotech Community
Cook Pharmica LLC is a biopharmaceutical contract manufacturer of mammalian cell-culture products. Cook Pharmica's mission is to provide process development, flexible manufacturing, and analytical services to the global biotech community, enabling its partners to bring their life-saving discoveries to patients. Founded in 2004, Cook Pharmica is a privately held, wholly-owned subsidiary of Cook Incorporated.
Cook Pharmica LLC is a biopharmaceutical contract manufacturer of mammalian cell-culture products. Cook Pharmica's mission is to provide process development, flexible manufacturing, and analytical services to the global biotech community, enabling its partners to bring their life-saving discoveries to patients. Founded in 2004, Cook Pharmica is a privately held, wholly-owned subsidiary of Cook Incorporated.
The current cGMP manufacturing facility was designed to support clinical and small-scale commercial products. Within the manufacturing area are two (2) 2,500L, one (1) 600L stainless steel bioreactors, and disposable bioreactors ranging in size up to 100L. The facility's design incorporates disposable technologies, segregated production rooms, innovative wall pass-throughs and uni-directional flow of operators, and equipment and supplies to reduce the risk of contamination.
Cook Pharmica's development group offers a variety of mammalian and microbial development services, such as: cell line or strain development, clone selection, cell line adaptation, media optimization, process development, purification development, analytical development, and pre-clinical manufacturing.
Additional contract services offered are analytical and microbial testing, CGMP cell banking, stability storage and testing, and regulatory assistance with submissions.
Centrally located in Bloomington, Indiana, Cook Pharmica offers a new level of transparency by giving clients the opportunity to monitor projects when away from the facility through secure Internet webcams positioned to give full visibility at each stage of production. Cook Pharmica is committed to maintaining strict compliance to regulatory agency guidelines and cGMP procedures, as well as providing the highest levels of quality assurance and quality control in all functions of our facility.
With a current facility of 124,000 square feet that is expandable to 450,000 square feet, and a second independent building with an additional 450,000 square feet, Cook Pharmica is well positioned and committed to expand production capacity and capabilities to meet the needs of customers.
Contact Information:
Cook Pharmica LLC
1300 S. Patterson Drive
P.O. Box 970
Bloomington, IN 47402-0970
Tel: 877.312.2665 (domestic)
812.355.6746 (international)
Fax: 812.336.7167
Email: busdev@cookpharmica.com
Website: www.cookpharmica.com
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
